Pharmacogenetic Effect on the Pharmacodynamics of Glibenclamide

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01242137

Enrollment

Registered

2010-11-16

Start date

2009-10-31

Completion date

Unknown

Last updated

2010-11-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes

Brief summary

Glibenclamide is metabolized by the hepatic enzyme P450 CYP2C9 to less active form. Polymorphism of this enzyme demonstrated clinical significance when examined on other drugs from the sulfonylurea drug family, to whom Glibenclamide is included. The investigators assumption is that patients with less active alleles of the enzyme may show lower dose requirements of the drug for glycemic control, when compared to patients homozygotes to wild-type alleles.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

20 Years to 90 Years

Healthy volunteers

Inclusion criteria

* Tx with metformin and glibenclamide

Exclusion criteria

* Tx which affecting the P450 2C9 action * Renal failure

Design outcomes

Primary

Measure	Time frame
HbA1c	2 years

Countries

Israel

Contacts

Primary ContactAmit Tirosh, Dr

tiroshamit@gmail.com972-52-4748989

Outcome results